(Q28200051)

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

The role of cyclooxygenases in inflammation, cancer, and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Cyclooxygenase-2 in human non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Identification and isolation of rat bone marrow-derived mast cells using the mast cell-specific monoclonal antibody AA4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Interaction of substance P with epidermal growth factor and fibroblast growth factor in cyclooxygenase-dependent proliferation of human skin fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Identification of the hemangioblast in postnatal life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

COX-2 inhibitors. A new class of antiangiogenic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021

Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.021